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Sonmar 5-Aminolaevulimic acid (ALA)-induced porphyrin photosensitisation is an attractive option for
photodynamic therapy (PDT) since skin photosensitivity is limited to 1-2 days. However. early clinical results
on colon tumours using the maximum tolerated oral dose of 60 mg kg-' showed only superficial necrosis.
presumably owing to insufficient intratumoral porphyrin levels, although inadequate light dosimetry may also
be a factor. We undertook experiments using ALA. 25-400 mg kg-' intravenously. to establish the threshold
doses required for a PDT effect. Laser light at 630 nm (100 mW. 10-200 J) was delivered to a single site in the
colon of photosensitised normal Wistar rats at laparotomv. The animals u-ere killed 3 days later and the area
of PDT-induced necrosis measured. No lesion was seen with 25 mg kg- 'The lesion size increased with larger
ALA doses and with the light dose but little benefit was seen from increasing the ALA dose above
200 mg kg- or the light dose above 100 J. Thus there is a fairly narrow window for optimum doses of drug
and light. Further experiments showed that the PDT effect can be markedly enhanced by fractionating the
light dose. A series of animals was sensitised with 200mgkg-' ALA and then treated with 25J. With
continuous irradiation. the lesion area was 13 mm'. but with a single interruption of 150 s the area rose to
94 mm with the same total energy. Results were basically similar for different intervals between fractions
(10-900 s) and different numbers of fractions (2-25). This suggests that a single short interruption in the light
irradiation may dramatically reduce the net light dose required to achieve extensive necrosis.
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Photodynamic therapy (PDT) is a promising non-thermal
laser technique which produces localised tissue necrosis with
light following administration of a photosensitising drug. The
drug is activated by light of a specific wavelength matched to
its absorption spectrum. In the presence of oxygen. the
activated photosensitiser causes the production of the cyto-
toxic species, singlet oxygen (Weishaupt et al., 1976). Animal
studies have shown that. in contrast to thermal techniques
(as with the Nd: YAG laser) or radiotherapy, which usually
affects all parts of the wall of a viscus. damaging collagen
fibrils and smooth muscle, PDT is more selective, sparing the
collagen fibrils and hence enabling healing predominantly by
regeneration (Barr et al.. 1987a). However, the present status
of PDT is far from ideal. Besides the problems of precise
light delivery and monitoring there are still difficulties in
finding the ideal sensitiser. Clinically, the most used sen-
sitisers are the derivatives of haematoporphynrn (HPD).
Efforts have been directed at identifying the active compo-
nent and it has been variously described as dihaemato-
porphyrin ether (Dougherty et al., 1984) or ester (Kessel,
1985). But there are several disadvantages regarding this
sensitiser, in particular cutaneous photosensitivity may last
for up to 3 months. Furthermore, an ideal sensitiser should
have high tumour selectivity, which is not achieved by HPD
(or indeed by any of the currently available photosensitisers)
and therefore damage to normal tissue also occurs, although
this may be acceptable if it is accompanied by safe healing.
which is usually the case (Bown, 1990).
5-Aminolaevulimnc acid (ALA) itself is not a sensitiser but
a naturally occurring precursor in the haem biosynthetic
pathway. In this pathway the synthesis of ALA is controlled
by a regulatory feedback inhibition (Rimington. 1966; Mar-
riott. 1968). By administering excess exogenous ALA to both
in vitro systems and whole animals. it has been shown that
the natural regulatory mechanism can be bypassed and the
final stage in the synthesis, the conversion of protoporphyrin
IX (PPIX) to haem involving the enzyme ferrochelatase, can
become overloaded. As a result, porphyrin intermediates of
the biosynthetic pathway, particularly PPIX. accumulate
(Malik and Djaldetti, 1979; Sima et al.. 1981). PPIX is a
potent photosensitiser. Successful photosensitisation has been
demonstrated not only in in vitro experiments (Malik and
Lugaci, 1987) and animal tumour models (Bedwell et al..
1992) but also in clinical trials. Topical or systemic applica-
tion of ALA in the treatment of basal cell carcinomas (Ken-
nedy and Pottier 1992) or tumours of the mouth (Grant et
al., 1993) respectively showed promising results. We have
also shown that PDT with ALA can produce necrosis in
gastrointestinal tumours (Regula et al., 1995). However, these
preliminary results showed that the effect of PDT using ALA
at the maximum oral dose that could be tolerated is very
superficial (typically only 1 mm depth of necrosis) compared
with results using HPD. The purpose of this paper is to look
at ways in which the treatment conditions using ALA might
be varied to get deeper necrosis. particularly as our own
recent laboratory experiments have demonstrated that we can
elicit up to 8 mm of necrosis in transplanted tumours in the
hamster pancreas (Regula et al.. 1994). Two approaches were
used, optimising the total drug and light doses and frac-
tionating the light dose.
Initially, the relative importance of the drug and light dose
was studied. In previous studies using aluminium sul-
phonated phthalocyamnne (AlSPc) we have shown that there
is a threshold tissue concentration of photosensitiser required
to produce photodynamic damage in the normal colon with a
specified light dose (Barr et al.. 1987b). This effect has been
ascribed to photodegradation (also referred to as photo-
bleaching) and is potentially a key factor in improving the
selectivity of PDT since it allows normal tissue adjacent to
tumour to be spared if the sensitiser dose is below the
threshold level (Barr et al.. 1990). For higher doses of AlSPc,
there is reciprocity between the light dose and tissue concen-
tration of photosensitiser. so if the tissue concentration of
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photosensitiser is increased. then reduction of the light dose
by the same factor produces the same size lesion. Several
investigators haxe shox-n this reciprocity in both in lvitro
(Henderson et al.. 1983: Gibson and Hilf. 1985) and in vivo
studies (Cowled and Forbes. 1985). Fingar and Henderson
(1987) shoxwed reciprocity for drug and light dose in studies
using haematoporphyrin derixatixe as the sensitisinz drug for
drug concentrations above a certain threshold. as for our
results with AlSPc. Another group demonstrated different
threshold lexels for different tumours. but could not establish
reciprocity for the drug and light dose (Gossner et al.. 1994).
Our aim >-as to see if the treatment x alues used clinically w-ith ALA wxere too close to the threshold. so that results
might improxe bv increasing x-alues for the drug or light
dose.
The second part of the programme >-as designed to look at
the influence of fractionating the light dose. Recent results
using ALA-induced PPIX (van der Veen et al.. 1994) and
HPD (Pe et al.. 1994) suggest that delixering the light dose in tw-o fractions might enhance PDT effects. Other w-orkers
using Photofrin haxe obserxed an enhanced tumour response
wxith modulated irradiation (Foster et al.. 1991). Howexer no
detailed studv has -et been reported on a systematic com-
parison of a range of fractionated irradiation protocols. Our
purpose xwas to examine different wxays in wxhich the light
dose might be dixided to see if this was likelv to lead to anv
useful advances in treatment using ALA-induced porphyrin
photosensitisation.
NMaterials and methods
5-,ALA x-vas obtained as a hN-drochloride (formula wxeight
167.6. 98°o pure powxder) from Sigma (Poole. UK). It w-as
dissolxed in physiological strength phosphate-buffered saline
(PBS: pH 2.8) and used wxithin 12 h. It>-as administered x-ia
a tail vein. The dose of photosensitiser ranged from
25-400mg mkg- and the concentration w-as adjusted to main-
tain the xolume of injection betw-een 0.3 and 0.5 ml to ensure
accuracv. All studies w-ere performed on female Wistar rats
supplied by the Imperial Cancer Research Fund. Their age
ranzed from 4 to 8 wxeeks and their weeight ranged from 140
to 170g. Injections of the photosensitiser u-ere carried out
under inhalation anaesthesia with fluothane (Zeneca. Macc-
lesfield. Cheshire. UK.) Photodx-namic therapy u-as camred
out during laparotomy under general anaesthesiau-ith intra-
muscular Hypnorm (fentanyl and fluanisone: Jansen Pharma-
ceuticals) and diazepam. PPIX fluorescence was imaged ex vis o in flattened strips of colon using a cooled slou--scan
charge-coupled dexice (CCD) camera (Wright Instruments.
model 1. resolution 600 x 400 pixels. 14 bit)u-ith a 50 mm
Olympus macro lens The technique has been described
previouslv in studies on AlSPc. also in normal rat colon
(Bedu-ell et a!.. 1991). Strips of 4cm lenathu-ere taken from
fixe animals. cut lonaitudinally. opened and placed flat onto
glass slides for imazinL: tu-o animals receix-ed 200 mg kg-
ALA ix. and a 50 J liht dose at 4 h post-administration (as
described below). andu-ere immediatelv sacrificed with the
4 cm sections taken from the laser-treated area: tu-o animals
received the same ALA dose but no light dose and u-ere
sacrificed at 4 h; one animal onlx received an injection of
PBS in order to assess background fluorescence lexels. The
colon stripsuwere snap frozen in liquid nitrogen and stored at
-202C before imazing. Fluorescenceu-as excited at 488 nm
usinz a 1 mA Ar ion laser beam expanded uniformly oxer
the specimen. and detected u-ith a 10 nm bandpass filter
centred at 633 nm corresponding to the main fluorescence
band of PPIX and eliminating potential interference from
reduced photoprotoporphxrin photoproducts. An IBM PC
clone wxith a high resolution colour monitor controlled the
camera operation and wxas used for digital image processing.
display and storage. Fluorescence wxas digitally quantified by
either line or box superimposition on areas of interest. In 0iio
fluorescence spectra xk-ere recorded using a Perkin-Elmer
spectrofluorimeter (LS-50B) equipped w-ith a bifurcated
optical fibre bundle for remote fluorescence sensing.
Phiotodi namic trherapi
The light source used >-as a pulsed (12 kHz) copper xapour
pumped dye laser (Oxford Lasers. Oxford. UK). The output x-as tuned to 630 nm and delivered via a 200 gm fibre passed
through the colon w-all and just touching the normal mucosa
on the opposite side. The fibre was maintained at approx-
imately 90 to the mucosal surface. Any faeces present were
eased au-ay from the irradiation zone. The rest of the
abdominal x-iscera >-as shielded from for-ward light scatter by
interposition of a piece of opaque paper. Only one site in the
colon x-as treated in each animal. approximately 1 cm distal
to the caecum.
In the first study wxe v-aried the drug and enerpg dose.
Power output from the fibre tip was 100 mW and the total
irradiation time varied from 100 to 2000 s giving a total
energy delivery of 10-200 J per animal. After each treatment
the power output was checked to make sure there had been
no significant drop of power during treatment. The time
interxal before PDT after sensitisation with ALA depended
on the drug doses used and varied from 1 to 4 h (Loh et al..
1992). Irradiation wxas performed at the time of peak PPIX
concentration. Animals with the lowest concentration of
ALA (25 mg kgr i.x-.) were treated after 1 h. those gixen
50 mgkg after 1.5 h. those gixen 100 and 200mgk after
2 h and those wxith the highest concentration of 400 mg k2-'.
after 4 h. Three to fixe animals were treated for each com-
bination of Xariables tested. Unsensitised control animals
were irradiated usin2 similar light doses to exclude thermal
effects. Another group of animals received sensitiser only to
exclude any microscopic or macroscopic effect owing to ALA
alone. After treatment. animals were allowxed to recover and
kept in standard laborator- conditions until killed at 72 h
wxhen mucosal damaze. xxhen present. wxas at a maximum
(Barr et al.. 19871). .At post mortem. 3 cm of the colon distal
to the caecum was excised and opened along the mesenteric
border for macroscopic inspection. The specimens were laid
out on a piece of card and the area of the PDT-induced
lesions determined by taking the longest (a) and the shortest
diameter (b) of the lesions wxhich were approximately ellip-
tical and then calculating the area by the formula it ab 4
(Barr et al.. 1987b). A small number of representative speci-
mens wxas subsequently fixed in formalin and prepared for
conxentional light microscopy to confirm the macroscopic
findings.
In the second series of experiments. the efficacy of different
wxays of fractionating the light dose was assessed. A light
dose of 25J (100mA. 250s) and druz dose of 200mgkg-'
ALA wxere used as these xxere knoxxn to give a 13 mm lesion
in normal colon applying the light in a single fraction and
that small increases in either of these xalues would give a
considerable increase in lesion size. Initially. the light dose of
2 J was divided into txxo or fixe equal fractions. with inter-
xals of 10. 50. 150 300 and 900 s between fractions. Next. the
number of fractions xas xaried from 1 to 25 (25J x 1.
12.5 J x 2. 5 J x 5. 2.5 J x 10. 1 J x 25) xxith a fixed interval
of 50 s betxxeen fractions. Finally. only one interval was used
but at different times durinn treatment so the light fractions
wxere not all the same (5J then 20J. 12.5J then 12.5J. 20J
then -,J and 25 J in one fraction).
To assess the effect of light fractionation at ALA doses
closer to those used clinically. a small number of experiments
was also done at ALA doses of 50 and 100 mg kg- i.v. All
animals wxere killed 7'2 h after laser treatment and the area of
the PDT lesions measured at post mortem. Fixe animals wxere
used for each set of xalues tested.
Results
Threshold studies
Lesions xxere seen in the treated colons three days after PDT
as well defined. oxal shaped. necrotic ulcers. The maximum
and minimum diameter of necrosis was measured macroscop-ically in all specimens. In the limited number of specimens
examined microscopically, there was always close correlation
between the dimensions of the lesion as measured macros-
copically and microscopically. and so for the remainder of
the study, only macroscopic measurements were made. The
area of necrosis was plotted as a function of the applied
energy for each ALA dose and is shown in Figure 1. With
the lowest drug dose of 25 mg kg-', there was no difference
in lesion size compared with unsensitised control animals
irradiated with the same light doses (50, 100 or 150J). For
higher drug doses, initially the photodynamic effect increased
with increasing light dose. but then reached a plateau (Figure
1). The same data is plotted in Figure 2 to show the area of
necrosis as a function of the administered dose of ALA. For
the higher energies of 100 and 150 J, a significant increase of
the lesion size over that seen in controls could be achieved if
the ALA dose was 50 mg kg-' or more. For the lower ener-
gies, this required elevating the dose to 100 mg kg-' (75 and
50J) or 200 mg kg-' (25 J).
Photodegradation of ALA-induced PPIX was studied
using ex vivo fluorescence imaging. Figure 3 shows that with
a 50 J light dose the PPIX fluorescence was reduced by a
factor of 3 in the centre of the stnrp (corresponding to the
laser fibre position) and bleaching was evident over an extent
of about 1 cm. A fluoresence emission spectrum of the same
strip (excitation wavelength 400 nm) was recorded ex vivo.
The central laser-treated region was probed with the excita-
tion beam from the fluorimeter which showed the appearance
of a new band around 675 nm which was not present in
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colon were observed at 636 and 704 nm. An identical in vivo
spectrum was also recorded from the exposed colon of an
anaesthetised rat (200 mg kg-' ALA. 2 h i.v.). An excitation
spectrum of untreated colon was recorded from 600 to
650 nm using detection at 700 nm which showed that peak
PPIX fluorescence excitation efficiency occurs at 635 nm; at
630 nm the efficiency was only 10% lower. thus little should
be gained by using 635 instead of 630 nm for PDT treatment.
Fractionated irradiation studies
In the second part of these studies we examined the influence
of fractionating the light dose. Table I shows the results
using just two fractions of light, but varying the interval
between fractions from 10 to 900 s. Table II shows the results
of dividing the light dose into five equal fractions. but once
again varying the interval between fractions from 10 to 900 s.
Table III shows the results of varying the number of frac-
tions from 1 to 25. with equal fractions and a fixed interval
of 50 s between fractions. Table IV shows the results using
just two fractions with an interval of 300 s with the same
total light dose of 25 J, but varying the size of the first
fraction from 5 to 20J. Finally. Table V shows the results
using lower doses of ALA (50 and 100mgkg-') compared
with those found using 200mgkg-'.
eated specimens. For comparison, the two fluorescence ALA is an attractive prospect as a photosensitising agent and
ima observed with ALA-induced PPIX in untreated rat as skin photosensitivity is limited to 1-2 days. there are few
risks of serious toxicity (as it is found in so many mam-
malian cells) and it can be given by mouth. Nevertheless, the
maximum bolus dose that can be tolerated by mouth in
Control patients is about 60 mg kg-'. Higher doses cause nausea with
25 mg kg-1 ALA occasional vomiting and transient elevation of liver enzymes
50 mg kg-1 ALA (Regula et al.. 1995). However, our clinical studies on
100 - 100 mg kg-1 ALA tumours of the gastrointestinal tract have shown that even
1 200mgkg-'ALA using 60mgkg-'. it is not possible to produce necrosis that --.- 400 mgkg- AA *--is more than 1 mm deep (Regula et al., 1995). In contrast, we
75- . - achieved 8 mm depth of necrosis in transplanted tumours in - ..~ the hamster pancreas (Regula et al.. 1994) using an oral dose
50---* of 400mgkg-' ALA. These results indicate that the drug
-------s~ ~ ~~~~doses used clinically were too low. This may be improved
when an intravenous preparation of ALA is available for
25- 5f -- ~~~4clinical use, particularly as the dose required intravenously is
likely to be about half that needed orally to achieve the same
o________*_______-_______-___-___-____ tissue levels of PPIX (Loh et al., 1993a). However, the tissue
o 50 100 150 200 levels may still be relatively low. The purpose of the present
Energy dose (J) investigation was to study the thresholds for drug and light doses required to get a PDT effect in normal rat colon and to
Figure 1 Area of necrosis vs irradiation energy in normal rat
colon after PDT at five different doses of ALA. Each point
represents the mean of measurements from five animals. Standard
errors were <± 20%.
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o , Fiure 3 Fluorescence image of ALA-induced PPIX-sensitised
0 100 200 300 400 normal rat colon with the mucosa facing after in Oi-o laser
Drug dose (ALA mg kg-' i.v.) treatment to the central section, 50 J and 200 mg kg- ALA.
Fluorescence was excited at 488 mm and detected at 630am. The
Figure 2 Area of necrosis in normal rat colon after PDT. Same false colour scale is shown at the top (white represents high
data as in Figure 1 but redrawn to show the variation of damage levels, red low levels of PPIX). The white bar corresponds to
vs the dose of ALA. Standard errors were <± 20%. 1 cm.Facors influencing PDT dfect
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Table I Area of necrosis produced in normal rat colon with a drug dose of 200 mg kg-'
ALA i.%-. and irradiation with a light dose of 25 J. The light dose was split once and the
duration of the break vanred from 1Os to 15 min
Duration of interruption None 10 s 50 s 50s 5min 15 min
Area of necrosis (mm-) 13 ± 2 89 ±23 53 ± 7 94 ± 13 70 ± 13 52 ± 13
Table n Area of necrosis produced in normal rat colon with a drug dose of 200 mg kg-'
ALA i.%- and irradiation with a light dose of 25 J. The light dose was split into five equal
fractions and the duration of the breaks varied from 1Os to 15 min
Duration of interruptions None 10 s 50 s 150 s 5 min 15 min
Area of necrosis (mmn) 13±2 19±7 26±8 50±8 55±8 54±7
Table III Area of necrosis produced in normal rat colon with a drug dose of
200 mg kg-' ALA i.v. and irradiation with a light dose of 25 J. The total
energy dose of 25 J was split into a different number of fractions (1-25). The
duration of the breaks was constant at 50 s
Number of fractions 1 2 5 10 25
Area of necrosis (mm) 13±2 53±7 26±8 49±7 44±8
Table IV Area of necrosis produced in normal rat colon With a
drug dose of 200 mg kg- ALA ix. and irradiation with a light dose
of 25 J. The light dose was split once for 5 min. The first fraction
was varied from 5 to 25J
First energy dose applied (J) 5 12.5 20 25
Area of necrosis (mm-) 93 ± 14 70 ± 13 47 ± 10 13 ± 2
see if it was possible to enhance the PDT effect by varying
the treatment conditions.
In the first senres of experiments we studied the size of
PDT lesions produced as a function of the light dose for a
range of doses of ALA and also as a function of the dose of
ALA for a range of light doses. As would be expected, in
general. the lesion area increased with the delivered light
dose. This was true for ALA doses of 50 mg kg-' or more,
but with 25 mg kg-'. the lesion was never larger than that
seen in unsensitised control animals, suggesting that there is a
threshold between these two doses. This loss in reciprocity
between the light and drug dose is most likely because of
photodegradation of the PPIX dunrng treatment as shown in
Figure 3 where most of the PPIX over a 1 cm zone at the
treatment site has been photodegraded by a light dose of
50 J. Similar results have been obtained with AlSPc (Barr et
al., 1990; Bedwell et al., 1991) although the threshold dose
for AlSPc is much lower at about 0.5 mg kg-'.
It is difficult to extrapolate directly from rats to humans to
correlate absolute tissue levels of PPIX with the administered
dose of ALA without chemical extraction data. However we
do have fluorescence photometric data recorded using the
same calibration conditions from frozen sections (Loh et al..
1993a, 1993b; Regula et al., 1995) of rat colon and human
colonic biopsies which indicate that the maximum dose we
used clinically (60 mg kg' by mouth) is very close to the
threshold level found in the present experiments. Therefore it
is perhaps not surprising that the clinical effects were so
superficial. Nevertheless, some PDT necrosis was seen in our
clinical study, which suggests that it may not be necessary to
raise the tissue levels of PPIX very much in order to get a
much larger effect. This problem may be solved when an
intravenous preparation of ALA is available for clinical use,
but another possibility is to give an iron chelating agent in
order to inhibit the conversion of PPIX to haem and thus
temporarily raise the tissue levels of PPIX. We have already
shown that the mucosal level of PPIX in the rat bladder can
be doubled by simultaneous administration of the iron
chelating agent 1,2-diethyl-3-hydroxypyridine-4-one (CP94)
(Chang et al., 1995), although this has not yet been tested
clinically.
At the upper end of the range of ALA doses used here,
doubling the dose of ALA from 200 to 400 mg kg' only
produced a marginal increase in the area of the mucosal
lesion. The most likely explanation for this is that the enzyme
systems in the synthetic chain from ALA to PPIX became
saturated thus limiting PPIX synthesis (Pottier et al., 1986),
so there is no point in giving an ALA dose more than
100-200mgkg-l. Thus there seems to be a fairly narrow
band of effective doses of ALA. in the range 50-200mg
kg-
General comments can also be made on the range of useful
light doses. For ALA doses greater than 25 mg kg-', the area
of necrosis increases with higher light doses, but little is
gained by increasing the light dose above 100 J (Figure 2).
Some effect is produced with 25 J. but with the lower doses
of ALA, at least 50 J is required to produce a lesion of
worthwhile size. Thus the useful range of light doses in this
experimental model is quite small, between 50 and 100 J.
Naturally, the light doses required in any particular situation
will depend on the geometry and on the organ being treated.
but these results do suggest that there is nothing to be gained
by large increases in the doses of light. It has been speculated
that the use of polychromatic light over the 600-700 nm
range might enhance PDT with ALA through the conco-
Table V Area of necrosis produced in normal rat colon with different drug doses (50.
100, 200 mg kg-' ALA i.v.) and irradiation with different light doses (50, 25 and 25 J
respectively). The treatment was interrupted once for 5 min after half of the energy
had been delivered
Drug dose 50 mg kg-' ALA i.v. 50 J continuous 2 x 25 J (5 min break)
Area of necrosis (mm-) 10±4 70±11
Drug dose 100mg kg-' ALA i.v. 25J continuous 2 x 12.5 J (5 min break)
Area of necrosis (mm-) 8 ± 3 63 ± 11
Drug dose 200 mg kg-' ALA i.v. 25 J continuous 2 x 12.5 J (5 min break)
Area of necrosis (mm) 13 ± 2 70 ± 13mitant excitation of photoactive photoproducts, but experi-
mental confirmation is still awaited. The presence of such
photoproducts is, however, evident from fluorescence excita-
tion studies from previous studies and this work where a new
fluorescence band was observed at 675 nm which is charac-
teristic of PPIX photoproducts (Konig et al., 1993). The use
of 635 nm excitation for ALA-induced PPIX PDT has
recently been advocated although our fluorescence excitation
studies indicate that any improvement over 630 nm should be
marginal unless absorption by other porphyrin photop-
roducts with slightly red-shifted absorption spectra becomes
important. Adequate light delivery in clinical practice will
require mapping of the target tissue to determine the true
extent of the area to be treated and then careful choice of
light delivery systems so that appropriate light doses can be
delivered to all relevant areas. This will require good-quality
definition of the extent of the pathology, by imaging or other
techniques, and then careful treatment planning by medical
physicists. However, even with good planning, treatment
times can be quite long to deliver the magnitude of doses
shown here to be the most appropriate.
The second part of the experimental work in this paper
was designed to assess one way in which PDT effects might
be enhanced using different light dose regimens. The tech-
nique studied was fractionation of the light dose. To max-
imise the chances of finding a useful effect, we used a fairly
high drug dose (200 mgkg-') and a low net light dose of 25 J
as from our earlier results, under these conditions, a small
enhancement of the PDT effect would give a large increase in
the lesion size.
Our results show that fractionating the light dose can
markedly enhance the PDT effect. By dividing the light into
two fractions, the PDT-induced ulcers were at least three
times larger and, in the case of a 150 s interval, an average of
five times larger in area (Table I); all of the observed in-
creases above the control value were well in excess of varia-
tions from experimental error. The data in Table II (when
five fractions were used) suggest that the effect increases
slightly as the duration of the break between fractions in-
creases, although in Table I (just two fractions) this trend is
not seen. Table III shows that the use of two fractions
divided by a 50s interval appears to be optimum with five
fractions being slightly less effective but still a factor of two
above the control value. It appears therefore that as long as
there is at least one break in treatment, the number of breaks
is not crucial.
Our experiments using 25 J and fractionated light pro-
duced lesions similar in size to those seen with continuous
light doses of more than 100J. Clinically, this could mean
that the light dose can be reduced by a factor of four, which
would be a considerable improvement. In our first
experiments with just two fractions, the length of the break
between fractions had little effect on the result (Table I)
although with five fractions the lesion size appeared to inc-
rease as the interval was increased from 10 to 150 s.
Experiments with larger numbers of animals would be
required to establish how important this effect is overall. It
could be relevant if new PPIX synthesis during the interval is
important, but this is unlikely as the interval durations
studied here are short compared with the time required for
PPIX synthesis (van der Veen et al., 1994).
The most likely reason for the effect of fractionation is
related to tissue oxygenation and vascular shut-down. (Star
et al., 1986). Oxygen is an essential component of the PDT
effect (Bown et al., 1986; Star et al., 1986) and we propose
that some vasoconstriction occurs during the first fraction
which partly relaxes during the break, so permitting reox-
ygenation of the target area and making it more susceptible
to PDT when the next light fraction is delivered. In effect, it
may be that the rapid onset of vasoconstriction soon after
the start of irradiation is actually protective owing to the
induced hypoxia; fractionation may then allow recovery of
normal oxygen tension. As vasoconstriction is progressive
during and after light exposure, the timing of the break
Fafjrs PDT oefd
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between fractions is likely to be important, but the optimum
time will probably vary a lot depending on the tissue being
treated, the concentration of photosensitiser, the irradiance
of the therapeutic light and various other factors. Further-
more, at certain light doses vasoconstriction is fully reversible
after irradiation is complete. Arteries and veins behave sligh-
tly differently: venular constriction is delayed compared with
arteriolar constriction as shown in studies on normal rat
cremaster muscle. (McMahon et al., 1994). These workers
also maintain that although tumour vessels are inherently
more fragile than in normal tissue, for example the cremaster
muscle, similar degrees of microvascular damage occur in
tumours implanted in the cremaster. Thus on this basis,
although we have not presented any data on tumour models,
we may be confident that our results on normal colon will be
of relevance to a colonic tumour model which is a study we
intend to pursue. Recently, studies of ALA-induced PPIX
vascular PDT effects have been reported in experimental
tumours (van der Veen et al., 1994) which demonstrated that
the magnitude of vascular damage is lower than observed
with exogenous photosensitisers under corresponding
tumoricidal conditions. The mechanisms involved in PDT-
induced vasoconstriction have been recently reviewed
(Wieman and Fingar, 1992) where it is noted that experi-
mental studies of ischaemic injury have shown that tem-
porary interruption of the regional blood flow leads to the
release of oxygen radicals upon reperfusion (Klausener,
1989). Such an effect may well be involved in the enhanced
response with fractionated PDT treatment if reperfusion is a
significant effect during the intervals between irradiation.
Previous studies have compared continuous wave and
pulsed laser sources for PDT and showed that there is no
difference in the effect with high repetition rates (I-10kHz
with pulse widths of 10-40 ns) although no PDT effect was
seen with a flashlamp pumped dye laser delivering higher
intensity pulses with a repetition rate of < 10 Hz and pulses
of 2-400ps duration (Cowled et al., 1984; Barr et al., 1989;
Ferrario et al., 1991; Panjehpour et al., 1993). This absence
of a PDT response at lower repetition rates was attributed to
saturation pumping of the sensitiser resulting in depopulation
of the ground absorbing state. This transient bleaching effect
however can only occur using high power pulsed excitation
as opposed to fractionated irradiation. Recently, there have
been two papers looking at the effect of dividing the light
into two fractions. Van der Veen et al. (1994) showed that
two light fractions 90 min apart enhanced the PDT effect in a
rat tumour model, but as the total delivered energy was
doubled when the light was fractionated, it is not clear
whether they were observing the same effect as us. Pe et al.
(1994) studied the destruction of a transplanted tumour in
mice after PDT with haematoporphyrin oligomer photosen-
sitisation comparing a single treatment for 20 min with two
30 min treatments separated by 1 h, the total light dose being
the same for the two regimens. They found that the frac-
tionated regimen considerably enhanced the PDT effect.
These results are certainly consistent with ours. Foster et al.
(1991) have also demonstrated, using modulated irradiation
with a period of 30s, that a markedly improved tumour
response with Photofrin can be achieved; although in our
studies modulation with a 50 s period also proved effective,
the degree of enhancement was greatest using a fractionated
protocol.
In conclusion, although the maximum tissue levels ofPPIX
achieved in patients using oral ALA are probably only at or
just above the threshold level for producing any effect, our
experimental results indicate once the threshold level is ex-
ceeded, the efficacy is much greater, which implies that a
useful clinical response could yet be achieved. In order to
increase the PPIX levels ALA could be given intravenously
and/or by coadministering an iron-chelating agent. Alterna-
tively, by fractionating the light dose, even with low PPIX
levels present, a significant improvement in the therapeutic
response may be achievable.Factors influening PDT df.cd
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